Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$1.22
$1.12
$0.82
$3.85
$327.27M0.234.10 million shs1.50 million shs
Organogenesis stock logo
ORGO
Organogenesis
$2.39
-1.6%
$2.47
$2.04
$7.08
$312.68M1.33783,361 shs1.18 million shs
SNDL Inc. stock logo
SNDL
SNDL
$1.25
-0.4%
$1.38
$1.24
$2.89
$321.75M0.921.44 million shs1.71 million shs
Tharimmune, Inc. stock logo
THAR
Tharimmune
$1.94
-5.8%
$2.82
$0.95
$9.08
$73.20M1.431.48 million shs774,941 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
0.00%-8.96%+15.09%-14.69%-69.58%
Organogenesis stock logo
ORGO
Organogenesis
-1.65%-8.78%-2.05%+1.70%-52.01%
SNDL Inc. stock logo
SNDL
SNDL
-0.40%-2.73%-10.43%-17.55%-22.19%
Tharimmune, Inc. stock logo
THAR
Tharimmune
-1.44%-11.97%-36.22%-39.59%+24.10%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$1.22
$1.12
$0.82
$3.85
$327.27M0.234.10 million shs1.50 million shs
Organogenesis stock logo
ORGO
Organogenesis
$2.39
-1.6%
$2.47
$2.04
$7.08
$312.68M1.33783,361 shs1.18 million shs
SNDL Inc. stock logo
SNDL
SNDL
$1.25
-0.4%
$1.38
$1.24
$2.89
$321.75M0.921.44 million shs1.71 million shs
Tharimmune, Inc. stock logo
THAR
Tharimmune
$1.94
-5.8%
$2.82
$0.95
$9.08
$73.20M1.431.48 million shs774,941 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
0.00%-8.96%+15.09%-14.69%-69.58%
Organogenesis stock logo
ORGO
Organogenesis
-1.65%-8.78%-2.05%+1.70%-52.01%
SNDL Inc. stock logo
SNDL
SNDL
-0.40%-2.73%-10.43%-17.55%-22.19%
Tharimmune, Inc. stock logo
THAR
Tharimmune
-1.44%-11.97%-36.22%-39.59%+24.10%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
2.40
Hold$4.67282.51% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.00
Hold$5.75140.59% Upside
SNDL Inc. stock logo
SNDL
SNDL
2.00
Hold$5.00301.61% Upside
Tharimmune, Inc. stock logo
THAR
Tharimmune
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest THAR, SNDL, AKBA, and ORGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
UpgradeStrong SellHold
7/1/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Reiterated RatingBuy$6.00
6/11/2026
SNDL Inc. stock logo
SNDL
SNDL
Reiterated RatingSell (E+)
5/28/2026
Organogenesis stock logo
ORGO
Organogenesis
Set Price Target$3.00
5/28/2026
Organogenesis stock logo
ORGO
Organogenesis
Initiated CoverageHold$3.00
5/28/2026
SNDL Inc. stock logo
SNDL
SNDL
UpgradeStrong SellHold
5/11/2026
Organogenesis stock logo
ORGO
Organogenesis
DowngradeHold (C)Sell (D)
5/8/2026
Organogenesis stock logo
ORGO
Organogenesis
DowngradeBuyNeutral
5/6/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Reiterated RatingSell (E+)
5/6/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
DowngradeHoldStrong Sell
4/29/2026
SNDL Inc. stock logo
SNDL
SNDL
DowngradeHoldStrong Sell
(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$236.20M1.39N/AN/A$0.12 per share10.17
Organogenesis stock logo
ORGO
Organogenesis
$564.17M0.55$0.64 per share3.76$2.36 per share1.01
SNDL Inc. stock logo
SNDL
SNDL
$937.39M0.34$0.11 per share11.10$3.06 per share0.41
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/AN/AN/AN/A$0.68 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$5.34M-$0.08N/AN/AN/A-8.83%-62.72%-5.66%8/6/2026 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$37.03M-$0.19N/AN/AN/A-0.84%9.63%4.76%8/6/2026 (Estimated)
SNDL Inc. stock logo
SNDL
SNDL
-$11.29M-$0.03N/A31.13N/A-1.19%-1.02%-0.85%7/28/2026 (Estimated)
Tharimmune, Inc. stock logo
THAR
Tharimmune
-$12.20M-$3.99N/AN/AN/AN/A-588.45%-264.41%N/A

Latest THAR, SNDL, AKBA, and ORGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.03N/AN/AN/A$48.85 millionN/A
8/6/2026Q2 2026
Organogenesis stock logo
ORGO
Organogenesis
-$0.35N/AN/AN/A$54.27 millionN/A
7/28/2026Q2 2026
SNDL Inc. stock logo
SNDL
SNDL
-$0.01N/AN/AN/A$166.26 millionN/A
5/7/2026Q1 2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.01-$0.03-$0.02-$0.03$51.67 million$53.54 million
5/7/2026Q1 2026
Organogenesis stock logo
ORGO
Organogenesis
-$0.29-$0.37-$0.08-$0.44$43.26 million$37.23 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
SNDL Inc. stock logo
SNDL
SNDL
N/AN/AN/AN/AN/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
1.33
1.40
1.33
Organogenesis stock logo
ORGO
Organogenesis
0.05
3.53
3.16
SNDL Inc. stock logo
SNDL
SNDL
0.12
4.84
3.25
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/A
4.98
4.98

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
SNDL Inc. stock logo
SNDL
SNDL
N/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
1.16%

Insider Ownership

CompanyInsider Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4.30%
Organogenesis stock logo
ORGO
Organogenesis
18.80%
SNDL Inc. stock logo
SNDL
SNDL
N/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
6.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
430268.26 million256.72 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950128.68 million104.48 millionOptionable
SNDL Inc. stock logo
SNDL
SNDL
2,751257.40 millionN/AOptionable
Tharimmune, Inc. stock logo
THAR
Tharimmune
237.73 million35.20 millionNot Optionable

Recent News About These Companies

Tharimmune Inc.
Tharimmune Approved as Super Validator on Canton Network
Tharimmune appoints Jacob Asbury as CFO
Tharimmune Appoints Jacob Asbury as New CFO
Crypto Company Creates Bizarre Drug

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$1.22 0.00 (0.00%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$1.23 +0.01 (+0.82%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$2.39 -0.04 (-1.65%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$2.38 -0.01 (-0.21%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

SNDL stock logo

SNDL NASDAQ:SNDL

$1.25 -0.01 (-0.40%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$1.25 +0.01 (+0.80%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

Tharimmune stock logo

Tharimmune NASDAQ:THAR

$1.94 -0.12 (-5.83%)
As of 07/24/2026

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.